Related Experiment Videos
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.
Michael Lawton1, Yoav Ben-Shlomo2, Margaret T May2
1Department of Population Health Sciences, University of Bristol, Bristol, UK Michael.Lawton@bristol.ac.uk.
Journal of Neurology, Neurosurgery, and Psychiatry
|November 23, 2018
Summary
Researchers identified four distinct Parkinson's disease subtypes using data from two patient cohorts. These subtypes show different motor progression rates and responses to medication, aiding future clinical trial stratification.
Area of Science:
- Neurology
- Data Science
- Clinical Research
Background:
- Parkinson's disease (PD) is a complex neurodegenerative disorder with a variable natural history.
- Identifying distinct subtypes of PD is crucial for understanding disease heterogeneity and optimizing treatment strategies.
- Previous attempts to subtype PD have faced challenges in replication and clinical relevance.
Purpose of the Study:
- To employ a data-driven approach to identify and characterize subtypes of early-stage idiopathic Parkinson's disease.
- To determine the natural history and prognostic indicators associated with each identified subtype.
- To validate these subtypes across two independent, large patient cohorts.
Main Methods:
- Utilized factor analysis followed by k-means cluster analysis on baseline data from 1601 (Tracking Parkinson's) and 944 (Discovery) early PD patients.
- Evaluated patients across motor, cognitive, and non-motor domains, with follow-up every 18 months.
- Assessed prognosis using random slope and intercept models to measure motor progression and levodopa response.
Main Results:
- Identified four stable and replicable PD subtypes: fast motor progression, mild motor/non-motor disease, severe motor/poor psychological/sleep, and slow motor progression (tremor-dominant).
- Cluster 1 exhibited the fastest motor progression (3.2 UPDRS III points/year), while Cluster 4 showed the slowest (0.6 UPDRS III points/year).
- Cluster 2 demonstrated the highest levodopa response (36.3%), and Cluster 4 the lowest (28.8%).
Conclusions:
- Four novel, well-replicated Parkinson's disease subtypes were identified in early-stage patients.
- These subtypes correlate with distinct motor progression rates and levodopa responses.
- Findings support patient stratification in future clinical trials and offer insights into PD pathophysiology.